Clinical trial · Interventional
Stereotactic Body Radiotherapy for Oligometastases From Colorectal Cancer
Phase II Study of Stereotactic Body Radiotherapy for Oligometastases From Colorectal Cancer
NCT02909114CI-TRIAL-00023960unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Single arms prospective phase II study of SBRT for oligometastatases from colorectal cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Stereotactic body radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Experimental group
- description
- SBRT for oligometastatases from colorectal cancer objectives
- interventionNames
- Radiation: Stereotactic body radiotherapy
Primary outcomes (1)
- measure
- local control assessed by RECIST
- timeFrame
- 3 years
Secondary outcomes (2)
- measure
- >= Grade 3 treatment-related adverse events as assessed by CTCAE v4.0
- timeFrame
- from radiotherapy start to complete treatment 90 days
- measure
- overall survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * 18-75 years * Eastern Cooperative Oncology Group (ECOG) performance score ≤ 1 * Diagnosis by pathological examination * Primary lesion is under control by surgery * Adequate blood counts: * White blood cell count ≥3.5 x 109/L * Haemoglobin levels ≥100g/L * Platelet count ≥100 x 109/L * Creatinine levels ≤1.0× upper normal limit (UNL) * Urea nitrogen levels ≤1.0× upper normal limit (UNL) * Alanine aminotransferase (ALT) ≤1.5× upper normal limit (UNL) * Aspartate aminotransferase (AST) ≤1.5× upper normal limit (UNL) * Alkaline phosphatase (ALP) ≤1.5× upper normal limit (UNL) * Total bilirubin (TBIL) ≤1.5× upper normal limit (UNL) Exclusion Criteria: * Primary lesion is not under control * Pancreatic carcinoma * Oligometastases could not be located * Pregnancy or breast feeding * Symptoms or history of peripheral neuropathy
References
Publications (0)
Data not yet available
No reference posted for this study.